← Back to Home

Tau Drug Shows a Signal on the Edge of Failure, Setting Up a Tougher Test for Alzheimer’s R&D

diranersen did not cleanly pass the preset bar in a Phase 2 trial, yet it lowered Tau and showed signs of slowing cognitive decline; this gives the Tau approach a renewed rationale for late-stage clinical development, while pushing the scientific question into a more rigorous Phase 3 trial.

By SURL BioNews

Alzheimer’s drug development in recent years has largely centered on amyloid protein, but patients’ decline in memory and function cannot be explained by a single protein alone. After Biogen and Ionis released results from the Phase 2 CELIA trial of their jointly developed drug diranersen, another long-difficult target, Tau protein, returned to the spotlight: this was not a clear victory, but it was a signal strong enough to let developers keep moving forward.

According to AP, the antisense oligonucleotide drug reduced Tau-related markers in about 400 patients with early Alzheimer’s disease and showed signs of slowing cognitive decline. However, the trial did not meet its originally defined dose-response goal, meaning researchers did not clearly see the expected pattern in which higher doses produced stronger clinical effects. For neurodegenerative diseases, this kind of result is often among the hardest to interpret: the biology appears to have been engaged, but the clinical evidence is not yet stable enough to change treatment standards.

Investor's Business Daily cited the company as saying that over 18 months of follow-up, diranersen slowed cognitive decline by 26% compared with placebo; other cognitive scales showed about a 42% to 50% slowing of decline. However, the same report also noted that the strongest effect on the main clinical scale, CDR-SB, appeared in the lowest-dose group. That is precisely why the market and researchers will remain cautious: if the efficacy signal does not show consistency across dose levels, later trials will have to answer whether this was random fluctuation, population differences, or whether there is truly a treatment window in which a lower dose is more appropriate.

diranersen’s appeal is that it does not clear plaques that have already formed, but instead uses antisense technology to reduce production of Tau protein. Biogen has described it as the first Tau-directed therapy candidate to show signals across cerebrospinal fluid biomarkers, reduced Tau tangles in the brain, and clinical impact. If this holds up in large trials, it would move Alzheimer’s treatment away from simply pursuing amyloid protein and toward pathological nodes closer to the downstream part of the disease cascade.

But usability and safety are also substantial issues. Reports indicate that diranersen must be administered intrathecally every six months, which is more invasive than typical oral drugs or intravenous infusions and will also affect real-world clinical adoption. On safety, dose-related confusion occurred in the trial, with most cases resolving in about one week; regulators and clinicians will carefully weigh this type of neurological side effect in older patients whose cognition is already impaired.

The next step will be a confirmatory Phase 3 trial. Biogen has said it plans to advance larger studies and has also discussed possible future combination with amyloid-targeting drugs. The direction is theoretically reasonable, because Alzheimer’s may require simultaneously addressing different layers of pathology; but combination therapy also means more complex questions around safety, cost, and attribution of efficacy.

What these results truly change is not that patients will be able to obtain a new drug tomorrow, but that the Tau approach has finally obtained a set of clinical signals sufficient to undergo testing in a larger trial. For a field full of failures, that is already significant; for medical evidence, however, it is still only the beginning.

References

  1. AP News
  2. Investor's Business Daily